Jesper Gromada
Inversor de Capital Privado en Third Rock Ventures LLC .
Perfil
Jesper brings 25 years of experience in drug development.
Prior to joining Third Rock, Jesper served as Chief Scientific Officer at Exonics Therapeutics (acquired by Vertex Pharmaceuticals) and Laronde Therapeutics.
Previously, Jesper held positions of increasing responsibility at Regeneron, Novartis, Eli Lilly and Novo Nordisk.
Jesper earned his Ph.D.
at the University of Copenhagen, Denmark.
He has contributed to the development of several clinical-stage drug candidates and marketed drugs.
Jesper has published over 200 research papers and patents.
Jesper is interested in combining discoveries in biology and technology for company creation and drug development.
He is impressed with the culture at Third Rock and the approach for build of innovative companies with proven abilities to develop impactful medicines.
Cargos activos de Jesper Gromada
| Empresas | Cargo | Inicio |
|---|---|---|
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Inversor de Capital Privado | 01/09/2022 |
Antiguos cargos conocidos de Jesper Gromada.
| Empresas | Cargo | Fin |
|---|---|---|
Laronde Inc.
 Laronde Inc. Miscellaneous Commercial ServicesCommercial Services Laronde Inc. is a company that aims to advance eRNA-based therapeutics through their powerful new platform called endless RNA (eRNA™). The company is based in Cambridge, MA and was founded by Noubar B. Afeyan. This platform can be programmed to make any therapeutic protein inside the body, making it the most versatile RNA platform for life-changing medicines. | Corporate Officer/Principal | 01/09/2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/10/2020 |
Exonics Therapeutics, Inc.
 Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/07/2019 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2006 |
Formación de Jesper Gromada.
| University of Copenhagen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Empresas privadas | 3 |
|---|---|
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Laronde Inc.
Laronde Inc. Miscellaneous Commercial ServicesCommercial Services Laronde Inc. is a company that aims to advance eRNA-based therapeutics through their powerful new platform called endless RNA (eRNA™). The company is based in Cambridge, MA and was founded by Noubar B. Afeyan. This platform can be programmed to make any therapeutic protein inside the body, making it the most versatile RNA platform for life-changing medicines. | Commercial Services |
Exonics Therapeutics, Inc.
Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jesper Gromada
